Source comparison
Sermorelin Before and After Real Results: Comparison
IGF-1 Levels (ng/mL) 120–160 (age 40–50 avg) 150–200 160–220 Restoration to upper-normal range; sustained elevation confirms pituitary responsiveness Visceral Fat (DEXA %) 18–22% (typical adult) 16–20% 15–18% Modest but meaningful reduction; requires caloric d
This comparison does not assign a generated winner or score.
- IGF-1 Levels (ng/mL)
- 120–160 (age 40–50 avg)
- 150–200
- 160–220
- Restoration to upper-normal range; sustained elevation confirms pituitary responsiveness
- Visceral Fat (DEXA %)
- 18–22% (typical adult)
- 16–20%
- 15–18%
- Modest but meaningful reduction; requires caloric deficit to manifest
- Lean Mass (kg)
- Baseline
- +0.5–1.5 kg
- +1.0–2.5 kg
- Preservation during deficit more significant than absolute gains
- Sleep Quality (SWS duration)
- 45–60 min/night
- 60–75 min/night
- 65–80 min/night
- Polysomnography-verified increase; correlates with recovery improvements
- Recovery Time (post-training)
- 48–72 hours (DOMS)
- 36–48 hours
- 24–36 hours
- Subjective but consistent across users; enables higher training frequency
- Skin Elasticity (dermatology scale)
- Moderate laxity
- Slight improvement
- Noticeable improvement
- Collagen synthesis marker; visible at 4+ months
- Sermorelin's effect on body composition is dose-dependent and ceiling-limited. Dosing typically ranges from 200–500 mcg subcutaneously before sleep. Higher doses don't produce proportionally greater results. The pituitary has a finite response capacity. Clinical data from endocrinology trials show that 300 mcg administered 5–7 days per week produces near-maximal IGF-1 elevation in most adults. Exceeding this provides diminishing returns and increases the risk of hypothalamic-pituitary axis desensitization over time.